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Abstract
Introduction: Mutational inactivation of the FBXW7/hCDC4 tumor suppressor gene (TSG) is common in many
cancer types, but infrequent in breast cancers. This study investigates the presence and impact of FBXW7/hCDC4
promoter methylation in breast cancer.
Methods: FBXW7/hCDC4-b expression and promoter methylation was assessed in 161 tumors from two
independent breast cancer cohorts. Associations between methylation status and clinicopathologic characteristics
were assessed by Fisher’s exact test. Survival was analyzed using the Kaplan-Meier method in addition to modeling
the risk by use of a multivariate proportional hazard (Cox) model adjusting for possible confounders of survival.
Results: Methylation of the promoter and loss of mRNA expression was found both in cell lines and primary
tumors (43% and 51%, respectively). Using Cox modeling, a trend was found towards decreased hazard ratio (HR)
for death in women with methylation of FBXW7/hCDC4-b in both cohorts (HR 0.53 (95% CI 0.23 to 1.23) and HR
0.50 (95% CI 0.23 to 1.08), respectively), despite an association between methylation and high-grade tumors (P =
0.017). Interestingly, in subgroups of patients whose tumors are p53 mutated or lymph-node positive, promoter
methylation identified patients with significantly improved survival (P = 0.048 and P = 0.017, respectively).
Conclusions: We demonstrate an alternative mechanism for inactivation of the TSG FBXW7/hCDC4, namely
promoter specific methylation. Importantly, in breast cancer, methylation of FBXW7/hCDC4-b is related to favorable
prognosis despite its association with poorly differentiated tumors. Future work may define whether FBXW7/hCDC4
methylation is a biomarker of the response to chemotherapy and a target for epigenetic modulation therapy.
Introduction
The F-box protein Fbxw7/hCdc4 is the substrate specifi-
city component of the SCFFbxw7/hCdc4 ubiquitin ligase.
SCFFbxw7/hCdc4 is responsible for the targeted ubiquityla-
tion and subsequent proteasomal degradation of an array
of oncoproteins that plays a critical role in oncogenesis,
such as cyclin E, c-Myc, Notch, and c-Jun among others
[1,2]. Substrate recognition is tightly regulated by phos-
phorylation of specific motifs in the target proteins called
Cdc4 phosphodegrons (CPDs) [3]. In line with its sup-
pressive function on oncoproteins, SCFFbxw7/hCdc4 is
inactivated by mutations in various tumor types [4]. The
majority of the mutations identified in Fbxw7/hCdc4 in
cancer specimens are missense mutations in the binding
pocket of Fbxw7/hCdc4 that prevent its interaction with
the phosphorylated CPD motif in the target proteins
[4,5].
The tumor suppressor function of Fbxw7/hCdc4 is
further underscored by frequent deletions of its locus at
chromosome 4q31, occurring in more than 30% of all
neoplasms [6]. Furthermore, targeted disruption of the
Fbxw7/hCdc4 gene has been shown to result in
enhanced genomic instability [7], a hallmark of cancer
cells. Studies in mice additionally support a tumor sup-
pressive activity of Fbxw7/hCdc4. Conditional inactiva-
tion of Fbxw7/hCdc4 in the T-cell lineage of mice
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promoted the development of thymic lymphomas [8]
and loss of one Fbxw7/hCdc4 allele was shown to accel-
erate tumor development in p53-heterozygous (p53+/-)
mice [9].
Little is known about the transcriptional regulation of
Fbxw7/hCdc4, but it has been shown to be a target of
p53 activation [10], establishing a direct link between
these two tumor suppressor genes (TSGs).
Three different Fbxw7/hCdc4 isoforms (a, b and g)
have been identified in mammals [11]. Each isoform cre-
ates proteins with identical substrate interaction
domains and a shared F-box motif linking to the com-
mon core ligase components (Skp1-Cul1-Roc1), but
encode unique N-terminal regions that localize each iso-
form to specific subcellular compartments [1,2]. Each
isoform is believed to possess its own promoter, which
could be differentially regulated in a cell type-specific
manner. Furthermore, isoform specific interactions with
several accessory proteins have been reported [12,13].
Importantly, mutations in specific isoforms have also
been identified in cancers, further strengthening the
notion of non-redundant functions for the three differ-
ent Fbxw7/hCdc4 isoforms [4,11,14].
Although mutations in Fbxw7/hCdc4 are frequent
events in diverse tumor types, including endometrial
carcinomas, cholangiocarcinomas, colorectal cancer and
T-cell acute lymphoblastic leukemia [4,7,11,15,16],
mutations are uncommon or absent in other malignan-
cies [4,17]. Thus, alternative mechanisms for inactivation
of Fbxw7/hCdc4 are likely to exist. Downregulation of
Fbxw7/hCdc4 expression has been reported in glioma
[18], gastric cancer [19] and colorectal [20], but the
mechanism(s) responsible for loss of expression of
Fbxw7/hCdc4 in cancer is not known.
Epigenetic inactivation of TSGs by promoter hyper-
methylation is a frequent event during tumorigenesis
[21,22]. In breast cancer, the most common malignant
disease in women, hypermethylation of specific genes
has been associated with the response to therapy, prog-
nosis, invasiveness and metastasis [23,24]. Hypermethy-
lation of TSGs in breast cancer is often associated with
clinicopathological factors predicting poor prognosis and
consequently serves as potential therapeutic targets for
demethylating agents. However, recent data also indicate
that methylation of specific TSGs can predict sensitivity
to chemotherapy thus opening up the potential for
DNA methylation as a biomarker to further individua-
lize cancer treatment in the future [25].
In the present study, we examined the possibility that
FBXW7/hCDC4 expression is epigenetically inactivated
through promoter specific hypermethylation in breast
cancer, a tumor type where Fbxw7/hCdc4 mutations are
not commonly observed [4]. We also explored the possi-
bility that aberrant promoter methylation associates with
clinical parameters and overall survival in breast cancer.
The results demonstrate that 51% of primary breast
tumor specimens have a methylated FBXW7/hCDC4-b
promoter with concomitant loss of FBXW7/hCDC4-b
expression. Interestingly, although methylation associ-
ates with high-grade tumors, univariate and multivariate
analysis suggest that FBXW7/hCDC4-b promoter methy-
lation might be a favorable prognostic marker in breast
cancer.
Materials and methods
Tumor specimens and clinicopathological features
A total of 161 primary breast tumor specimens from
two breast cancer cohorts were included in this study.
Among the 161 samples in which FBXW7/hCDC4-b
promoter methylation was analysed, RNA was available
from 139 samples, which was further processed for
cDNA synthesis and FBXW7/hCDC4-b expression ana-
lysis as described below. A total of 68 cases of primary
breast cancer were obtained from patients diagnosed at
the Department of Obstetrics and Gynecology of the
Innsbruck Medical University of Austria (cohort 1) and
93 samples were obtained from patients at the Depart-
ment of Pathology of Uppsala University, Uppsala, Swe-
den (cohort 2). All patients underwent resection of the
tumor during surgery and specimens were processed by
pathologists at the affiliated hospital. Samples were snap
frozen in liquid nitrogen and stored at -80°C until RNA
and DNA extraction.
Cohort 1: Clinicopathologic features for this collection
of samples have been previously reported [26]. Patients
were diagnosed and operated on between 1990 and
2001 and the median age of the patients included in this
study was 64 years (range 33 to 88). Patients were trea-
ted in compliance with the national recommendations at
the time. Forty-one and 27 patients underwent a lum-
pectomy or a mastectomy, respectively. Thirty-eight
patients received loco-regional radiation. Thirty-five
patients received adjuvant combination chemotherapy
CMF (cyclophosphamide, methotrexate and 5-fluoroura-
cil), and 33 patients received adjuvant anti-hormonal
therapy. All samples were collected during surgery in
compliance with and approved by the Institutional
Review Board and with informed consent from the
patients. p53 was sequenced in tumor samples from
cohort 1 using either genomic DNA or cDNA as a tem-
plate with primers derived from intronic or gene specific
sequences (primer sequences can be obtained from the
authors upon request). PCR amplification and purifica-
tion was performed as previously described [4,15] and
sequenced at Eurofins MWG Operon (Eurofins MWG
Operon, Ebersberg, Germany).
Cohort 2: Breast cancer patients were diagnosed and
operated on between 1987 and 1989 at Uppsala
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University Hospital, Uppsala, Sweden. The median age
for the patients used in this study was 63 years (range:
28 to 94). Clinicopathological data and treatment have
been previously reported [27,28]. Briefly, patients were
operated on and received postoperative radiotherapy.
When adjuvant tamoxifen was given, some patients
received this treatment as part of a randomized study
comparing two versus five years, and chemotherapy,
mostly CMF according to standards in those days
[27,28]. Ethical permission was obtained from the ethical
committee at Karolinska Institute and with informed
consent from the patients. Data on p53 mutational sta-
tus in this series of breast tumor specimens have been
described [27].
Genomic DNA and RNA from fresh frozen tumor tis-
sue were isolated as previously described [4,15]. RNA
from various normal tissues was purchased from ABI
(Applied Biosystems, Foster city, CA, USA). Normal
breast tissue was obtained from reduction surgeries as
well as from noncancerous tissue DNA extracted from
paraffin-embedded breast cancer specimens. cDNA was
synthesized from 2 μg of total RNA using Superscript
First-strand Synthesis System (Invitrogen, Carlsbad, CA,
USA).
Cell lines, transfections and treatments
A total of 60 human cancer cell lines, originating from
breast, brain, prostate, kidney, blood, cervix, lung, skin,
bone and thyroid (See Additional file 1 for details), were
analyzed for FBXW7/hCDC4 expression and promoter
methylation. Cell lines were maintained and cultured
according to American Type Culture Collection (ATCC)
guidelines or as previously described [15,29]. All plasmid
transfections were performed using LT1 transfection
reagent (MIRUS, Madison, WI, USA), as recommended
by the manufacturer’s protocol. For experiments evaluat-
ing the effects of demethylation, cell lines maintained in
appropriate media were treated with 5-aza-2’-deoxycyto-
dine (5-aza-dC) (Sigma-Aldrich, St Louis, MO, USA) or
DMSO for three to five days.
Cloning
A 1.6 kb genomic region (-1293 bp to +309 bp from the
transcription start site (TSS)) of the FBXW7/hCDC4-b
isoform containing 18 CpG sites was amplified by PCR,
cloned into the pSC-A vector (Stratagene, Santa Clara,
CA, USA) and sequenced. The specific primers used for
amplification of the FBXW7/hCDC4-b promoter, were
as follows; FP1: 5’-GCC ATT TAC CAC CAT AGC
AGA GAG TA-3’, RP1: 5’-GCT ATG TGA TTG TGT
GTG TAT GCC-3’. Two shorter versions of the promo-
ter, containing 11 and 6 CpGs respectively, were also
amplified using the following forward primers, FP2:
5’-AGA CTT ATT TGT GGA AAT GTT CCT TGC
TA or FP3: 5’-GCA TTG CTG AAT CCT GGA CTG
CAC C and the reverse primer, RP1. Each promoter
region was subcloned into pGL3 vector (Promega, Madi-
son, WI, USA) after KpnI and BglII restriction digestion
(New England Biolabs, Ipswich, MA, USA). The result-
ing promoter constructs were termed pGL3hCDC4b-1.6,
pGL3hCDC4b-0.8. and pGL3hCDC4b-0.6. The pRL-
SV40 Renilla luciferase plasmid was obtained from Pro-
mega (Madison). PCR reactions were performed in a
BioRad thermocycler (Techne, Burlington, NJ, USA).
Luciferase assay
Luciferase activities in cell lysates from cells transfected
with different pGL3 constructs and pRL-SV40 control
plasmid were measured in a luminometer (VICTOR3,
PerkinElmer, Waltham, MA, USA) using the Dual-
Luciferase Reporter Assay System according to the man-
ufacturer’s protocol (Promega). Luciferase activities were
quantified and fold change was averaged from at least
three separate experiments performed in triplicates.
DNA methylation analysis
Methylation of the FBXW7/hCDC4-b promoter was
examined in cell lines, normal breast and primary
tumors by several methods. Bisulfite-modified genomic
DNA was prepared and CpG methylation was analysed
by bisulfite-sequence analysis as previously described
[30,31]. The methylation status of the complete
FBXW7/hCDC4-b promoter was determined by
sequence analysis of at least five individual clones from
cell lines if not otherwise stated. For screening of rela-
tive methylation levels, the McrBc restriction enzyme
(New England Biolabs) was used. McrBc recognize and
cuts pairs of purine-methyl cytosines (recognition
sequence RmC(N)55-103R
mC) and subsequent PCR ampli-
fication of methylated DNA segments in comparison
with an unmethylated segments thus denotes the methy-
lation status of the region of interest. Briefly, 200 ng of
genomic DNA was treated with or without 0.5 unit of
McrBc enzyme for 1 hr at 37°C in the reaction buffer
provided by the supplier. Each sample was heat inacti-
vated and subsequently amplified by PCR using FP1 and
RP1 primers. PCR amplification was performed with 100
ng DNA as template in the following conditions; two
minutes denaturation and 30 cycles of amplification
(94°C for 30 s, 64°C for 30 s, and 68°C for one minute)
using Titanium™taq DNA polymerase (BD) (Becton
dickinson, Franklin Lakes, NJ, USA). PCR products were
resolved on agarose gels and band intensities were quan-
tified by Image J software (ImageJ, U. S. National Insti-
tutes of Health, Bethesda, Maryland, USA) [32] The
mean McrBc ratio (band intensity of McrBc digested
DNA divided by undigested DNA) in unmethylated
DNA samples obtained from normal breast tissue and
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tumor-derived cell lines (verified through bisulfite
sequence analysis) was 0.808 with a standard deviation
(SD) of 0.11. Test samples were judged as methylated if
their McrBc ratio had a decreased value greater than 2
SD as compared to the unmethylated control samples.
A McrBc methylation ratio of 0.6 was thus used as a
cutoff. The McrBc results were also confirmed by
restriction digestion of PCR products using Taq I and
HpyCHIV enzymes (cuts methylated CG11 and CG18,
respectively, data not shown). To verify the effect of
promoter methylation on FBXW7/hCDC4-b expression,
luciferase reporter constructs were methylated in vitro
with Sss I methylase (New England Biolabs) as pre-
viously described [33]. Screening for methylation of
FBXW7/hCDC4-a in primary tumor samples was car-
ried out using McrBc restriction digestion analysis. The
FBXW7/hCDC4-a promoter was amplified using pri-
mers; FA1: 5’-AGA CCC AGG AAG AGG AAA AGA
GGA-3’, RA1: 5’-TGG GTT GGT TCC CTT CCT CCT
TC-3’ and analysed for methylation as described above.
Expression analysis
FBXW7/hCDC4 isoform-specific primers and TaqMan
probes for quantitative real-time PCR analysis of differ-
ent FBXW7/hCDC4 isoforms have been described [12].
The ΔΔCt method of relative quantification was per-
formed to determine relative mRNA expression in each
sample. The relative expression level of each FBXW7/
hCDC4 isoform was obtained by normalizing the
expression of FBXW7/hCDC4 mRNA to GAPDH
mRNA expression. Primers and conditions for semi-
quantitative RT-PCR of FBXW7/hCDC4 isoforms have
been described [29]. Amplification of GAPDH mRNA
served as an internal control. Oestrogen and progester-
one receptor (ER/PR) status was determined by immu-
nohistochemistry as previously described [34].
Statistical analysis
The association between patient clinicopathological
characteristics (such as oestrogen receptor, progesterone
receptor, lymph node involvement, grade, stage and age)
and methylation status of the FBXW7/hCDC4-b isoform,
in addition to P53 mutation, was determined using the
Fisher’s exact test. Differences in FBXW7/hCDC4-b
expression between methylated and unmethylated
groups were analysed by means of the (non-parametric)
Wilcoxon-Mann-Whitney test. Univariate analyses of
survival were conducted by use of the Kaplan-Meier
method. Further, the risk of dying in women with
methylation of the FBXW7/hCDC4-b isoform compared
with women with unmethylated FBXW7/hCDC4-b iso-
form was modelled by use of multivariable proportional
hazards (Cox) models, adjusted for possible confounders
of survival such as age at diagnosis, date of primary
tumour surgery, oestrogen receptor and progesterone
receptor status, and P53 mutation. An arbitrary level of
5% statistical significance was used. Finally, data pre-
paration and analysis was done using the SAS Statistical
package, version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Identification of promoter methylation and loss of
FBXW7/hCDC4-b expression in tumor cell lines
Mammals express three Fbxw7/hCdc4 splice variants
designated a, b, and g, each encoding a unique N-term-
inal protein sequence fused to 10 downstream exons,
suggesting non-redundant functions as mentioned above.
Semi-quantitative RT-PCR analysis of the different
FBXW7/hCDC4 isoforms revealed substantial differential
expression of the FBXW7/hCDC4-b transcript in specific
cell lines from various tumor tissues (Figure 1a). The
immortalized breast epithelial cell lines IME and MCF10,
expressed high levels of FBXW7/hCDC4-b compared to
some breast cancer cell lines with low or absent FBXW7/
hCDC4-b expression (Figure 1a, left). This variation in
mRNA expression was not generally observed for the
FBXW7/hCDC4-a isoform, which was the most
abundant and ubiquitously expressed FBXW7/hCDC4
transcript in most cell lines examined (Figure 1a).
As previously reported [35,36], the beta isoform was
expressed at very high levels in tissue from normal brain
(Figure S1 in Additional file 1). Significant expression
was also observed in tissues from normal breast, ovary
and cervix, compared to other tissues with low (spleen,
thyroid, liver) or absent (skeletal muscle) FBXW7/
hCDC4-b expression (Figure S1 in Additional file 1). To
examine whether loss of FBXW7/hCDC4-b expression
correlated with hypermethylation of its promoter, we
first examined the sequence 1.3 kb upstream and 0.3 kb
downstream of the transcription initiation start site in
FBXW7/hCDC4-b. Eighteen CpG sites were distributed
throughout this region (Figure 1b). To this end, we used
bisulfite sequence analysis to determine the methylation
status of each of these CpGs in five different cell lines
with low/absent FBXW7/hCDC4-b expression (HeLa,
U266, PEER, Daudi and DLD1) and five cell lines with
high expression (IME, MB-468, T-ALL, 293A and
MOLT4). Regarding the methylation status, cell lines
were found to fall into two distinct groups; one demon-
strating methylation of the majority of CpGs (90 to
100%) correlating with low expression, and the other
exhibiting mostly unmethylated CpGs and showing high
expression (Figure 1c). Screening for methylation was
also carried out using the restriction enzyme McrBc, a
methylation specific endonuclease, which cuts DNA
containing 5-methylcytosine in the context of a second,
arbitrarily spaced methylcytosine, and does not cleave
unmethylated DNA. As shown in Figure 1d, screening
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for methylation of this region with the McrBc enzyme
recapitulated the methylation results obtained by bisul-
phate sequence analysis.
Assessing methylation by McrBc digestion in 50 addi-
tional cell lines from various tissues (Table S1 in Addi-
tional file 2) demonstrated methylation in 26 of 60
(43%). FBXW7/hCDC4-b expression was next analyzed
by real time reverse transcription PCR. A significant dif-
ference in expression between methylated and unmethy-
lated cell lines (Figure 2a, P = 0.0001) was found with
lower expression in methylated (median expression =
0.02, range; 0 to 0.9) compared to unmethylated cell
lines (median expression = 1.6, range; 0 to 8.1). No cor-
relation between methylation of the FBXW7/hCDC4-b
promoter and expression of FBXW7/hCDC4-a mRNA
was found (data not shown).
To establish a direct link between methylation and silen-
cing of FBXW7/hCDC4-b expression we treated HeLa,
BT-20, U2OS and BT-474 cells with the DNA methyla-
tion inhibitor 5-aza-dC. As can be seen in Figure 2b,
5-aza-dC treatment increased FBXW7/hCDC4-b mRNA
expression levels in methylated cell lines (HeLa and BT-
20), with an initial low expression, in contrast to the
unchanged high FBXW7/hCDC4-b levels of unmethy-
lated cell lines (U2OS and BT-474) (Figure S2A in Addi-
tional file 3). Demethylation of the promoter upon 5-
aza-dC treatment was confirmed by McrBc digestion
(Figure 2c) and sequencing of bisulfite treated DNA
Figure 1 Differential expression of FBXW7/hCDC4-b mRNA and promoter methylation in tumor cell lines. (a) Semi-quantitative RT-PCR
analysis of FBXW7/hCDC4 isoforms, left, in normal breast, immortalized mammary epithelial cells and breast cancer cell lines, right, in human
cancer lines from different origins. GAPDH was amplified as an internal control. (b) Schematic map of the FBXW7/hCDC4-b promoter region
around the transcription start site (TSS). CpG dinucleotides are depicted. PCR primers used for amplification of the promoter are indicated as
arrows (FP1 and RP1). The translational start codon (ATG), centromere (Cen) and telomere (Tel) are marked. (c) real-time PCR showing the
relationship between FBXW7/hCDC4-b expression (top) and promoter methylation (bottom); Methylation is presented as the percentage of
methylated CpG sites based on bisulphate sequence analysis of genomic DNA from different cancer cell lines. The degrees of methylated
cytosines or unmethylated cytosines are indicated by black or white boxes, respectively. (d) Representative gel analysis of PCR product (1.6 kb)
from McrBc digested (+) genomic DNA in comparison with undigested (-) control DNA. Note the lack of amplification of McrBc digested DNA
from methylated cell lines (HeLa and DLD1) in comparison to unmethylated cell lines (IME and T-ALL).
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(data not shown). As a control, FBXW7/hCDC4-a
mRNA expression was measured after 5-aza-dC treat-
ment. No significant increase of FBXW7/hCDC4-a levels
was observed in any of the cell lines examined (Figure
S2B in Additional file 4 and data not shown).
To confirm that the FBXW7/hCDC4-b promoter
region possesses transcriptional activity, we performed
luciferase reporter assays with the 1.6 kb genomic region
covering all 18 CpGs (Figure 1b) and two shorter pro-
moter regions (0.8 and 0.6 kb), being deletion constructs
of the 1.6 kb region mentioned above. Robust reporter
activity was observed in cell lines of different origins
with all three constructs, albeit a reduced activity was
observed with the shorter promoter constructs (data not
shown). To further evaluate the effect of methylation on
promoter activity, we next performed reporter assays
using transient transfection of constructs where the
FBXW7/hCDC4-b promoter was methylated in vitro
using the Sss I methylase as previously described [33].
As shown in Figure 2d, in vitro methylation suppressed
reporter activity confirming that methylation of the pro-
moter abrogates FBXW7/hCDC4-b expression.
Together, these data demonstrate that CpG-methyla-
tion correlates with loss of FBXW7/hCDC4-b expression
in tumor cell lines. These data also indicate that methy-
lation could be a significant factor in regulating
FBXW7/hCDC4-b expression in some malignancies,
including breast cancer.
FBXW7/hCDC4-b promoter methylation in primary breast
cancer specimens
Based on the results above, we next explored the occur-
rence and role of FBXW7/hCDC4-b methylation in pri-
mary breast cancer specimens. To exclude the possibility
that methylation detection is affected by contaminating
noncancerous cells, we first analysed FBXW7/hCDC4-b
Figure 2 Inverse correlation between FBXW7/hCDC4-b mRNA expression and promoter methylation in tumor cell lines. (a) Cancer cell
lines were divided into two groups based on the ratio of band intensity of McrBc digested cell line DNA divided by undigested DNA. The
expression levels were lower in the methylated (M) group than in the unmethylated (UM) group (P = 0.0001). Horizontal lines, median
expression value of each group. P value was calculated using the nonparametric Mann-Whitney U test. (b) 5-aza-dC treatment upregulate
FBXW7/hCDC4-b mRNA levels in methylated cell lines. Mean ± SD. (c) 5-aza-dC demethylate the FBXW7/hCDC4-b promoter as evident by
restoration of PCR amplification of McrBc digested DNA. (d) pGL3E luciferase reporter assay without or with FBXW7/hCDC4-b promoter region in
vitro methylated using SssI enzyme (filled bars). Relative fold change in luciferase activity +/- SEM is shown.
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promoter methylation in normal breast tissues (obtained
from normal breast reductions) by McrBc digestion (Fig-
ure 3a) and bisulfite sequence analysis (data not shown).
Importantly, methylation was absent in normal breast tis-
sues as well as in noncancerous tissue DNA extracted
from a paraffin-embedded breast cancer specimen (Figure
3a and data not shown). We next analyzed FBXW7/
hCDC4-b methylation in two cohorts of breast cancer spe-
cimens in which RNA was available and FBXW7/hCDC4
mRNA expression could be analysed. A total of 71 out of
139 (51%) patient samples showed methylation of the pro-
moter as defined by McrBc digestion, compared to its
undigested control (Figure 3a). Tumor specimens were
classified as low or high methylation (see Materials and
methods for details on quantification and classification of
promoter methylation), divided into two groups and com-
pared with the mRNA expression levels of FBXW7/
hCDC4-b. Similar to the results in tumor cell lines, a sta-
tistically significant difference was found between the
groups (Figure 3b, P = 0.0002). The methylated group
showed significantly lower expression of FBXW7/hCDC4-
b (median expression = 0.13, range; 0 to 1.43) as compared
to the unmethylated group, which had higher expression
levels (median expression = 0.30, range; 0 to 8.83).
These results demonstrate that there is a significant
inverse correlation between promoter methylation and
FBXW7/hCDC4-b expression in primary breast cancer
specimens.
Figure 3 Inverse correlation between FBXW7/hCDC4-b mRNA expression and promoter methylation in primary breast tumor
specimens. (a) Representative analysis of FBXW7/hCDC4-b promoter methylation in normal breast (N), breast tumor specimens (T), immortalized
breast epithelial cells (IME) and a cancer cell line (HeLa). Genomic DNA was incubated with (+) or without (-) McrBc enzyme and the promoter
was PCR amplified (1.6 kb). The cleavage pattern indicates differential methylation in tumor samples (T1, T2; methylated and T3, T4;
unmethylated) and a lack of methylation normal breast (N1, N2). (b) Relationship between FBXW7/hCDC4-b mRNA expression levels and
promoter methylation in primary breast tumors. Samples were stratified by relative methylation status (UM; unmethylated group, N = 68, M;
methylated group, N = 71, see materials and methods for classification of methylation). FBXW7/hCDC4-b expression levels (normalized to GAPDH
mRNA) were lower in the methylated group compared to the unmethylated group (Mann-Whitney U test, P = 0.0002). Bars from each box
extend to largest and smallest expression levels. Outliers are plotted as asterisks (*).
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Correlation of FBXW7/hCDC4-b methylation with
clinicopathological characteristics
Data on methylation status and clinicopathological para-
meters were available for a total of 161 tumor specimens
(68 cases from cohort 1 and 93 cases from cohort 2).
The associations between FBXW7/hCDC4-b methylation
and clinicopathological features are summarized in
Table 1. Methylation was significantly associated with
high-grade tumors (P = 0.017) and a trend towards an
association with estrogen receptor-negative tumors was
also observed in the methylated group (Table 1). No sig-
nificant associations were observed between methylation
of FBXW7/hCDC4-b with age, stage and lymph node
status (Table 1) or with p53 mutational status (Table S2
in Additional file 5). As previously reported [27], p53
mutation was associated with high-grade and receptor-
negative (ER and PR) tumors (Table S2 in Additional
file 5).
Correlation of FBXW7/hCDC4-b methylation and prognosis
To evaluate whether methylation of FBXW7/hCDC4-b
was an independent prognostic factor in breast cancer,
we examined the significance of methylation using mul-
tivariate analysis, including adjustment for other factors
known to be associated with clinical outcome. As the
cohorts from the two centers were treated during differ-
ent time periods, and thus partly using different treat-
ment protocols, this outcome analysis was performed
separately for the two groups. This also enabled a vali-
dation of the findings in the two independent cohorts.
In both cohorts, methylation of FBXW7/hCDC4-b was
found to be associated with an approximately 50%
decreased risk of death (cohort 1 hazard ratio 0.53 (0.23
to 1.23) and cohort 2 (HR) 0.50 (95% CI 0.23 to 1.08),
Table 2). We also performed log rank analysis of
Kaplan-Meier curves for overall survival in defined prog-
nostic subgroups. Methylation was associated with a sig-
nificantly improved overall survival in patients with
lymph node metastasis, in cohort 1 (Figure 4a, P =
0.017). In this cohort, patients with ER receptor-negative
tumors additionally demonstrated a clear trend,
although not statistically significant (P = 0.111, data not
shown), for improved survival in methylated tumors. In
line with the data from cohort 1, the overall survival in
women with lymph node-positive tumors from cohort 2
was higher in the group whose tumors demonstrated a
methylated FBXW7/hCDC4-b promoter, compared to
women with an unmethylated promoter (Figure 4b).
However, this difference was not statistically significant,
possibly due to the smaller number of patients in this
subgroup from cohort 2 (n = 35 out of 93), in compari-
son with cohort 1 (n = 41 out 68). No clear conclusions
could be drawn from cohort 2 regarding the prognostic
significance for FBXW7/hCDC4-b methylation in the
ER-negative group, due to the limited number of
patients (n = 13). Methylation was also associated with a
significantly improved overall survival in the p53
mutated subgroup in cohort 2 (Figure 4c, P = 0.048).
Thus, in two subgroups with known adverse prognostic
features (that is, patients with lymph node metastasis
and patients whose tumors harbored p53 mutation)
FBXW7/hCDC4-b methylation was found to be asso-
ciated with improved survival. No association between
survival and methylation of FBXW7/hCDC4-b was
Table 1 Association of FBXW7/hCDC4-b promoter
methylation in 161 primary breast cancer patients with
clinicopathological features
UM (%) M (%) P
Age
≤67 37 (45.1) 45 (54.9) 0.27
>67 43 (54.4) 36 (45.6)
ER
Negative 17 (37.7) 28 (62.3) 0.08
Positive 61 (54) 52 (46)
Unknown 2 1
PR
Negative 17 (40) 25 (60) 0.21
Positive 61 (52.5) 55 (47.5)
Unknown 2 1
LN
Negative 41 (50.6) 40 (49.4) 0.75
Positive 36 (47) 40 (53)
Unknown 3 1
Grade
I/II 64 (55.1) 52 (44.9) 0.017
III 13 (32.5) 27 (67.5)
Unknown 3 2
Stage
I/II 58 (52.2) 53 (47.8) 0.18
III 9 (36) 16 (64)
Unknown 12 12
* Fisher’s exact test. UM, unmethylated; M, methylated; ER, estrogen receptor;
PR, progesterone receptor; LN, lymph node.
Table 2 Methylation status and overall survival in
primary breast cancer patients using Cox proportional
hazard model
Patients F (%) Deaths HR 95%CI* P
Cohort 1
UM 30 (44.1) 14 1.0(ref)
M 38 (55.9) 12 0.53 0.23 to 1.23 0.14
Cohort 2
UM 50 (53.8) 21 1.0(ref)
M 43 (46.2) 28 0.50 0.23 to 1.08 0.08
F Cohort 1 (n = 68) and Cohort 2 (n = 93).
* Adjusted for age, period of diagnosis, ER, PR and p53 status. HR, hazard
ratio; UM, unmethylated; M, methylated.
Akhoondi et al. Breast Cancer Research 2010, 12:R105
http://breast-cancer-research.com/content/12/6/R105
Page 8 of 13
found in patients with lymph node negative tumors
(Figure S3 in Additional file 6). No clear conclusions
could be drawn from cohort 1 regarding the prognostic
significance for patients with p53 mutation and FBXW7/
hCDC4-b methylation due to the limited number of
patients and events in the p53 mutated/FBXW7/hCDC4-
b methylated subgroup.
Discussion
F-box proteins are substrate recognition subunits of the
SCF ubiquitin ligases with well-established functions in
cell cycle control and tumor development [37,38]. We
recently performed a comprehensive analysis of primary
human tumors and showed mutations in the F-box gene
FBXW7/hCDC4 to occur with an overall frequency of
6% in diverse tumor types [4]. FBXW7/hCDC4 muta-
tions were first identified in breast cancer and ovarian
cell lines [14,35]. However, analysis of more than 151
primary breast tumor specimens showed that FBXW7/
hCDC4 mutations are rare in this malignancy [4].
Several studies have reported reduction in FBXW7/
hCDC4 copy number due to deletion of chromosome 4q
[6,39]. However, loss of FBXW7/hCDC4 expression in
cancer can occur without genetic alteration [20], impli-
cating a possible role for epigenetic silencing of
FBXW7/hCDC4.
Figure 4 Kaplan-Meier analysis of overall survival in specific patient subgroups. (a) Overall survival rate for patients with methylated
FBXW7/hCDC4-b promoter was significantly higher than that for patients in the unmethylated group in lymph node positive patients from
cohort 1 (log rank test, P = 0.017). (b) Overall survival for patients from cohort 2 showed a similar trend as patients in cohort 1 but was not
statistically significant (log rank test, P = 0.72). (c) Patients with methylated FBXW7/hCDC4-b promoter and p53 mutation have improved survival
compared to patients with p53 mutation and unmethylated FBXW7/hCDC4-b promoter in cohort 2 (log rank test, P = 0.048).
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In this study, we report for the first time promoter
specific methylation of the FBXW7/hCDC4-b isoform in
primary breast tumors. Two independent cohorts of pri-
mary breast tumors were analyzed and promoter hyper-
methylation was found to correlate with downregulation
of FBXW7/hCDC4-b mRNA expression (Figure 3b).
Moreover, using DNA methylation inhibitors in intact
cells as well as in vitro methylation of promoter con-
structs in reporter assays, we demonstrate that FBXW7/
hCDC4-b expression is regulated by promoter hyper-
methylation (Figure 2). Loss of FBXW7/hCDC4 expres-
sion is unlikely to result from allelic imbalances of the
4q31 locus, as examination of >140 primary breast
tumors using Representational Oligonucleotide Microar-
ray Analysis (ROMA [40]), showed that FBXW7/hCDC4
is hemizygously deleted in less than 20% of primary
breast tumors (data not shown, A. Zetterberg and P
Lundin, personal communication).
In breast cancer ER/PR and HER-2/neu represent the
few established molecular markers used both for prog-
nostication as well as to predict the response to tamoxi-
fen and herceptin, respectively [41,42]. Aberrant DNA
methylation is a common event in cancer and a wealth
of recent data indicates that altered methylation of
TSGs in breast cancer is frequent, and that determina-
tion of such events can provide prognostic as well as
predictive information [23,24,43]. However, there is still
an urgent need for discovery of novel prognostic factors
and predictive biomarkers that give pre-treatment infor-
mation on the efficacy of adjuvant chemotherapy, which
is commonly applied to many patients with primary
breast cancer.
Methylation of TSGs often associates with adverse clin-
ical factors [44-46]. In line with this, in this study,
FBXW7/hCDC4-b promoter methylation significantly
was associated with high-grade tumors and also occurred
frequently in ER-negative tumors (Table 1). Interestingly,
despite this, multivariate survival analysis demonstrated
an association between methylation of FBXW7/hCDC4-b
and decreased risk of death (Table 2). As mentioned
above, the differences between the cohorts prohibited us
from combining the data. It will thus be important to
validate these findings in larger clinical cohorts.
Interestingly, sub-group analysis revealed that FBXW7/
hCDC4-b methylation identifies patients with a signifi-
cantly improved prognosis among patients whose
tumors demonstrated the adverse features of lymph
node metastasis and p53 mutation, respectively (Figure
4). This somewhat parallels previous findings from our
group [15] and others [47] in T-cell acute lymphocytic
leukemia (T-ALL), an ALL sub-group with relatively
poor prognosis. In this malignancy, mutational inactiva-
tion of FBXW7/hCDC4 in combination with NOTCH1
mutations predicts a favorable outcome [15,47].
One may speculate why methylation of FBXW7/
hCDC4-b in breast cancer associates with improved out-
come. One reason may be that methylated tumors have
a biologically less aggressive behavior. This seems less
likely, in light of our findings that these tumors are
overrepresented in subgroups of patients with high-
grade tumors, and possibly ER-negativity. In line with
this, we have preliminary data demonstrating an associa-
tion between FBXW7/hCDC4-b methylation and high
expression of the proliferation marker PCNA in breast
cancer (correlation coefficient r = 0.313, P = 0.022 (n =
52, cohort 1)). Thus, a more likely possibility is that
tumors with inactivated FBXW7/hCDC4-b may be more
responsive to the given adjuvant treatment. This could
also explain the greater impact of FBXW7/hCDC4-b
methylation on survival in cohort 1, compared to cohort
2, as a higher proportion of patients in cohort 1 were
exposed to adjuvant polychemotherapy (see materials
and methods and 27). Furthermore, a link between
FBXW7/hCDC4-b methylation and a tendency for
increased survival was found in patients receiving che-
motherapy and/or irradiation (Table S3 in Additional
file 7), as analyzed in cohort 1.
FBXW7/hCDC4 function has been directly linked to cell
cycle checkpoint controls, its inactivation resulting in
improper M phase progression, formation of micronuclei
and chromosomal instability [7]. Indeed, Finkin et al.
hypothesized that loss of FBXW7/hCDC4 might have
important effects on how cells respond to chemotherapeu-
tic drugs, and showed that exposure of cells lacking
FBXW7/hCDC4 to spindle toxins, such as taxol, com-
monly used in breast cancer treatment, renders cells more
susceptible to endoreduplication and polyploidy [48].
The recent advances and understanding of how cell
cycle checkpoints and DNA repair pathways respond to
chemotherapy-induced DNA damage has opened up
unprecedented opportunities for improved development
of personalized treatment [49]. This is for instance
exemplified in a recent elegant study that demonstrated
a synthetic lethal interaction between ATM and p53 in
response to cytotoxic drugs [50]. Remarkably, tumors
defective for both ATM and p53 were more prone to
drug induced cell killing and tumors with functional
ATM but non-functional p53 could be sensitized by
pharmacologic suppression of ATM signaling [50,51].
Similar results have been reported for other TSGs
involved in controlling genomic stability, such as the
inhibition of PARP-1 in BRCA1/2 deficient breast and
ovarian tumors which selectively kills the cancer cells
while sparing normal cells with a functional repair path-
way [52]. Together, these findings highlight the impor-
tance for a detailed knowledge of genetic defects in
tumors to identify those patients who will most likely
respond to specific genotoxic drugs.
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To date, defined Fbxw7/hCdc4 substrates are nuclear
proteins (that is, c-Myc, cyclin E) degraded by the
Fbxw7/hCdc4-a and/or Fbxw7/hCdc4-g isoforms [1,2],
whereas Fbxw7/hCdc4-b specific substrates still await
discovery. Fbxw7/hCdc4-b localizes to the cytoplasm
and could potentially target a pro-apoptotic substrate(s)
or a protein(s) involved in DNA damage signaling that
when stabilized sensitize tumor cells to chemotherapeu-
tic drugs. Interestingly, Mao et al. recently reported that
Fbxw7/hCdc4 targets the mammalian target of rapamy-
cin (mTor) for degradation [53]. The Fbxw7/hCdc4 iso-
form responsible for mTor degradation was not defined
in this study, but it’s noteworthy that mTor localizes to
the cytosol and that breast cancer cells with loss of
Fbxw7/hCdc4 were shown to be more sensitive to mTor
inhibitors [53].
We have just begun to understand the complex inter-
play between FBXW7/hCDC4, its target oncoproteins
and other critical cancer genes. For example, p53 is a
direct transcriptional regulator of FBXW7/hCDC4
expression [10]. However, the functional relationship
between these TSGs is still unclear and FBXW7/hCDC4
has also been suggested to act upstream of p53 [48].
Furthermore, a differential relationship with the various
FBXW7/hCDC4 isoforms is possible. A recent study in
gastric cancer revealed that patient samples with p53
mutations had lower FBXW7/hCDC4-a mRNA levels
and those patients also had a poor prognosis compared
with the other subgroups [19]. In line with these data,
in our analysis of breast cancer specimens, we also
found a statistically significant correlation (P = 0.0002)
between low FBXW7/hCDC4-a expression and p53
mutation. To exclude the possibility that downregulation
of FBXW7/hCDC4-a expression is due to promoter
methylation, we have analysed the FBXW7/hCDC4-a
CpG island for methylation. Methylation was not
observed in any of the primary breast tumor specimens
analysed, independently of FBXW7/hCDC4-a mRNA
levels, indicating that p53 mutational status is major
decisive factor in the regulation of FBXW7/hCDC4-a
expression in breast cancer (manuscript in preparation).
Interestingly, no significant association between the
expression (or methylation) of FBXW7/hCDC4-b and
p53 mutational status (Table S2 in Additional file 5 and
data not shown) was found, and as mentioned above,
methylation and loss of expression of FBXW7/hCDC4-b
was instead linked to increased survival in the p53
mutated group. Thus, although FBXW7/hCDC4-b is a
known transcriptional target of p53 [10], methylation of
the promoter likely predominates in transcriptional sup-
pression of FBXW7/hCDC4-b mRNA expression. In
summary, we have identified a previously not recognized
mechanism for inactivation of FBXW7/hCDC4 expres-
sion, namely promoter specific methylation with
potential prognostic significance in breast cancer. These
data suggest that methylation of the FBXW7/hCDC4-b
promoter predicts a favorable prognosis in breast can-
cer, particular in specific patient subgroups, despite the
association of FBXW7/hCDC4-b methylation with
adverse clinical parameters. Further studies will be
required to validate whether FBXW7/hCDC4-b methyla-
tion could serve as a biomarker for sensitivity to che-
motherapy in breast cancer.
Conclusions
This study provides new insights into the causes and
consequences of FBXW7/hCDC4 inactivation in breast
cancer. The FBXW7/hCDC4-b promoter is methylated
in approximately 50% of primary breast tumors and
methylation correlates with loss of FBXW7/hCDC4-b
expression. Furthermore, promoter methylation predicts
a favorable prognosis in breast cancer, particularly in
specific patient subgroups, despite the association of
FBXW7/hCDC4-b methylation with adverse clinical
parameters. The role of FBXW7/hCDC4-b methylation
in breast cancer progression and its potential function
as a novel biomarker for sensitivity to chemotherapy in
breast cancer needs further investigation.
Additional material
Additional file 1: Supplemental Figure S1. FBXW7/hCDC4-b expression
levels were examined by real-time PCR (and normalized to GAPDH mRNA
levels) in a panel of different normal tissues. FBXW7/hCDC4-b was
differentially expressed between tissues, with the highest expression in
brain and moderate expression in cervix, ovary and breast. Low or no
detectable expression was found in spleen, thyroid, liver and skeletal
muscle, respectively.
Additional file 2: Supplemental Table S1. Panel of cell lines analyzed
for FBXW7/hCDC4-b promoter methylation and expression.
Additional file 3: Supplemental Figure S2A. FBXW7/hCDC4-b
expression levels in unmethylated cell lines BT-474 and U2OS after 5-aza-
dC treatment. Mean ± SD.
Additional file 4: Supplemental Figure S2B. FBXW7/hCDC4-a
expression levels in methylated cell lines HeLa and BT-20 after 5-aza-dC
treatment. Mean ± SD.
Additional file 5: Supplemental Table S2. Association of p53 mutation,
clinicopathological features and FBXW7/hCDC4-b methylation in primary
breast cancer patients.
Additional file 6: Supplemental Figure S3. Kaplan-Meier analysis of
overall survival in lymph node negative patients from cohort 1 and
cohort 2.
Additional file 7: Supplemental Table S3. Association between FBXW7/
hCDC4-b methylation status and treatment outcome in breast cancer
patients (cohort 1).
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